Innovative therapeutics

sidebar_clinical_trials_geneticallydefinedcancer

Clinical Trial

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Read more »

Clinical Trial

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Read more »

Clinical Trial

Phase II Study of the PARP Inhibitor BMN 673 (Talazoparib Tosylate) in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
Read more »

Clinical Trial

First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered BMN 673 in Participants with Advanced or Recurrent Solid Tumors (PRP- 001)
Read more »

Clinical Trial

Phase 1, Two-Arm, Open-Label Study of Once Daily, Oral BMN 673 in Participants with Advanced Hematological Malignancies
Read more »

Top